GLP-1 Drugs Show Potential Links to Lower Cancer Risk in New Research
Recent studies presented at major oncology conferences suggest GLP-1 agonist drugs may reduce the risk of certain cancers, including obesity-related cancers and breast cancer. The findings represent an unexpected discovery, as these drugs were originally developed for type 2 diabetes and later marketed for weight loss. The research has prompted increased scientific interest in investigating whether GLP-1 drugs could serve as cancer prevention tools.
Multiple studies presented at the American Society of Clinical Oncology meeting and published in peer-reviewed journals have found associations between GLP-1 agonist use and reduced cancer risk. One study of over 161,000 obese patients without diabetes found a 41 percent reduction in obesity-related cancer diagnosis among those using GLP-1 drugs compared to those receiving diet and exercise counseling. A separate study of over 110,000 women undergoing breast imaging found that those taking GLP-1 medications had 31-35 percent lower odds of developing breast cancer. Researchers emphasize these are observational studies and do not definitively prove causation. The findings are described as potentially transformative by cancer research organizations, though experts note additional research is needed to determine whether GLP-1 drugs could prevent cancer recurrence or metastasis in patients already diagnosed with cancer.
What's missing
The mechanisms by which GLP-1 drugs might reduce cancer risk remain unclear and are not discussed in either source. Additionally, neither source addresses potential long-term safety concerns or adverse effects specific to cancer prevention use, nor do they discuss the timeline for potential regulatory approval of GLP-1 drugs for cancer prevention indications.
What different sources said
- Global News CanadaCenter
Can GLP-1s lower some cancer risks? What new research suggests
- Deutsche WelleCenter
Is there anything GLP-1 agonist drugs cannot do?
Related
CAR T-cell therapy puts lupus into remission in pioneering NHS trial
Five lupus patients in England have achieved remission after receiving CAR T-cell therapy, a genetically modified immune treatment, in an early NHS trial at University College London Hospitals. The therapy works by engineering patients' own T cells to destroy malfunctioning B cells, effectively resetting the immune system, and patients have remained well for over 18 months without lupus medication. If confirmed in larger studies, this could represent a potential cure for lupus and may be applicable to other autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
UK to Offer Meningitis B Vaccine to Million Young People Following Outbreak
The UK government has announced a one-off vaccination programme offering two doses of the meningitis B vaccine to approximately one million teenagers in their final school year and young people under 25 starting university, beginning in late July 2026. The decision follows an unprecedented outbreak in Kent and clusters in Dorset and Berkshire that resulted in three deaths, with all cases covered by the Bexero vaccine. The programme aims to protect those at highest risk during university entry, when increased social mixing and shared accommodation elevate transmission risk.
NHS Investigation Finds Gender Care Failures at Brighton GP Clinic, 78 Children Prescribed Medication Inappropriately
An NHS safety investigation found that a Brighton GP practice (WellBN) inappropriately prescribed gender-related medications to 78 children under 18 between February 2023 and December 2025, including some under age 13, often without proper face-to-face appointments or necessary medical oversight. The clinic lacked qualified clinicians and specialist support, failed to conduct required blood tests, and provided treatment that fell "far short of what could be considered safe or appropriate." NHS England has suspended prescriptions to children at the clinic and referred clinicians to medical regulators, highlighting systemic failures in a service created to address long waiting times for specialist gender care.